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Abstract
AIM
To evaluate the efficacy and safety of modified 
FOLFIRINOX as a second-line treatment for gemcita-
bine (GEM)-refractory unresectable pancreatic cancer 
(PC).
METHODS
This study was a prospective, multicenter, one-arm, 
open-label, phase Ⅱ trial. Patients with unresectable 
PC, who showed disease progression during GEM-
based chemotherapy were enrolled. All patients were 
administered FOLFIRINOX with reduced irinotecan 
and oxaliplatin (RIO; irinotecan 120 mg/m2 and oxa-
liplatin 60 mg/m2), which was set according to the 
phase Ⅰ study of FOLFIRINOX. The objective response 
rate (ORR), disease control rate (DCR), progression-
free survival (PFS), overall survival (OS), adverse events 
were evaluated. Additionally, changes in quality of life 
(QoL) were assessed using a questionnaire on QoL.
RESULTS
Between August 2015 and May 2016, a total of 48 
patients were enrolled. The median follow-up time 
was 259 d with a median of 8.5 cycles. The ORR and 
DCR were 18.8% and 62.5%, respectively, including 
one patient who showed complete remission. The 
median PFS was 5.8 mo [95% confidence interval (CI): 
3.7-7.9] and median OS was 9.0 mo (95%CI: 6.4-11.6). 
Neutropenia (64.6%) was the most common grade 3-4 
adverse event, followed by febrile neutropenia (16.7%). 
Although 14.6% of patients experienced grade 3 
fatigue, most non-hematologic AEs were under grade 
2. In the QoL analysis, the global health status score 
before treatment was not different from the score at 
the last visit after treatment (45.43 ± 22.88 vs  48.66 ± 
24.14, P  = 0.548).
CONCLUSION
FOLFIRINOX with RIO showed acceptable toxicity and 
promising efficacy for GEM-refractory unresectable PC. 
However, this treatment requires careful observation of 
treatment-related hematologic toxicities.
Key words: Pancreatic cancer; FOLFIRINOX; Clinical 
Trial, Phase Ⅱ; Chemotherapy; Gemcitabine refractory
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Core tip: For gemcitabine (GEM)-refractory unresectable 
pancreatic cancer (PC), there are limited options 
of second-line chemotherapy regimen. To find new 
treatment option for GEM-refractory unresectable 
PC, we conducted a multicenter phase Ⅱ trial, which 
evaluated the efficacy and safety of uniquely modified 
FOLFIRINOX with reduced irinotecan and oxaliplatin. In 
our results, FOLFIRINOX with reduced irinotecan and 
oxaliplatin showed acceptable toxicity and promising 
efficacy. With careful observation of treatment-related 
hematologic toxicities, this chemotherapy regimen is a 
promising option for patients with GEM-refractory PC 
after first-line treatment failure.
Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh 
MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study 
Group of Korean Society of Gastrointestinal Cancer. Multicenter 
phase Ⅱ trial of modified FOLFIRINOX in gemcitabin-refractory 
pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 
505­515  
URL: https://www.wjgnet.com/1948­5204/full/v10/i12/505.htm 
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INTRODUCTION
Pancreatic cancer (PC) is among the major causes of 
cancer-related deaths in the United States[1]. In South 
Korea, PC is the eighth highest-diagnosed cancer 
and the fifth most common cause of cancer-related 
death[2]. Metastatic pancreatic cancer (MPC) accounts 
for 60% of all cases; the median survival of patients 
with MPC is 3-6 mo. Systemic chemotherapy is pivotal 
for treating such patients; however, effective regimens 
remain limited. Recently, two first-line combination 
regimens-FOLFIRINOX [a combination of oxaliplatin, 
folinic acid (FA), irinotecan, and 5-fluorouracil (5-FU)] 
and nanoparticle albumin-bound (nab) paclitaxel in 
combination with GEM-prolonged survival compared to 
gemcitabine (GEM) monotherapy and became standard 
treatments[3,4]. However, the median progression-free 
survival (PFS) of these new treatment regimens was 
only 6.4 and 5.5 mo, respectively. 
Proper second-line treatment can improve survival 
of patients with locally advanced pancreatic cancer 
(LAPC) or MPC who fail first-line treatment. Although 
some previous phase Ⅲ trials showed survival improve-
ment with their study regimens, the standard treatment 
remains unclear[5-7].
Patients who received first-line FOLFIRINOX or nab-
paclitaxel plus GEM may benefit from a novel second-line 
treatment, although toxicity should also be considered. 
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FOLFIRINOX, a standard first-line treatment, has been 
proposed as a second-line treatment for patients with 
good performance status who failed GEM-based che-
motherapy. However, as the condition of many patients 
deteriorates after first-line chemotherapy, second-line 
therapy requires administration at attenuated doses 
and/or schedules, even in patients who maintain a 
preserved comorbidity profile. 
Standard FOLFIRINOX has limited broad use as 
a second-line therapy because of toxicity; it includes 
irinotecan (180 mg/m2), oxaliplatin (85 mg/m2), 5-FU 
(400 mg/m2 administered as a bolus followed by 2400 
mg/m2 administered as a 46-h continuous infusion), 
and leucovorin (400 mg/m2) every 2 wk[3]. Several 
FOLFIRINOX trials have investigated reducing dosa-
ges while maintaining efficacy[8-10]. However, studies 
focused on the efficacy and safety of a modified dose 
of FOLFIRINOX for patients with GEM-refractory PC 
are still rare. Therefore, we conducted a prospective, 
multicenter, one-arm, open-label, phase Ⅱ trial using 
a modified FOLFIRINOX with reduced oxaliplatin and 
irinotecan (RIO) to minimize adverse events (AEs). 
Our aim was to evaluate the efficacy and safety of 
FOLFIRINOX with (RIO) in patients with unresectable 
PC who had earlier been treated with a GEM-based 
regimen until disease progression. 
MATERIALS AND METHODS
Study population
This study was a prospective, multicenter, one-arm, 
open-label, phase Ⅱ trial and conducted in eight Korean 
university hospitals. The inclusion criteria for this study 
were patients between 19 and 75 years old; Eastern 
Cooperative Oncology Group performance status ≤ 
2; cytologically or histologically proven unresectable 
pancreatic adenocarcinoma that progressed after 
first-line GEM-based chemotherapy; adequate bone 
marrow function (white blood cell count ≥ 3500/µL, 
absolute neutrophil count ≥ 1500/µL, and platelet 
count ≥ 100000/µL); adequate hepatic function (total 
bilirubin ≤ 1.5 × the upper limit of the normal range 
[ULN], serum aspartate and alanine transaminase ≤ 
3 × ULN, and alkaline phosphatases ≤ 3 × ULN or ≤ 
5 × ULN in case of liver metastasis); adequate renal 
function (serum creatinine ≤ 1.5 mg/dL); and adequate 
cardiopulmonary function. Patients were excluded if 
they had a concurrent malignancy other than PC; a 
serious, uncontrollable medical condition; or a psychia-
tric disorder. The study was performed in accordance 
with the ethical guidelines of the 1975 Declaration of 
Helsinki. Written, informed consent was obtained from 
each participant after potential treatment complica-
tions had been fully explained. The institutional review 
boards at all participating institutions approved this 
study. This trial is registered with ClinicalTrials.gov, 
number NCT02440958.
Study endpoints
The primary endpoints were objective response rate 
[ORR; complete remission (CR) + partial response (PR)] 
and disease control rate (DCR; CR + PR + stable disea-
se (SD)). The secondary endpoints were PFS, overall 
survival (OS), changes in quality of life (QoL), and safety. 
OS was calculated from the date of enrollment until 
death from any cause. In the absence of an event, data 
were censored on the last day of survival confirmation. 
PFS was calculated from the initiation of treatment 
until either imaging-confirmed disease progression or 
death from any cause; in their absence, data for such 
patients were censored on the day of their last imaging 
procedure. 
Determination of study drug dose
In the phase Ⅰ study of FOLFIRINOX, febrile neutrope-
nia, prolonged (≥ 7 d) severe neutropenia, and severe 
non-hematologic AEs were not reported at a dose level 
of 120 mg/m2 irinotecan and 60 mg/m2 oxaliplatin[11]. 
Based on these data, we set the study drug regimen 
– FOLFIRINOX with RIO – to 120 mg/m2 irinotecan 
(66.6% of standard dose) and 60 mg/m2 oxaliplatin 
(70.5% of standard dose) with standard dose of bolus 
and infusional 5-FU. 
Treatment protocol and dose adjustments
Oxaliplatin was first administered as a 2-h intravenous 
infusion (IVF); 1 h later, irinotecan was administered 
as a 90-min IVF. Leucovorin (400 mg/m²) was admini-
stered as a 90-min IVF immediately after oxaliplatin 
and irinotecan. The 5-FU dose was a 400 mg/m2 bolus 
followed by 2400 mg/m2 administered over 46 h of IVF. 
Each cycle of FOLFIRINOX with RIO was administered 
every 2 wk and repeated until either evidence of pro-
gressive disease (PD), significant clinical deterioration, 
or withdrawal of patient consent. All patients routinely 
received palonosetron 30 min before the initiation of 
chemotherapy as a prophylactic anti-emetic agent. 
Atropine was administered to patients with irinotecan-
caused cholinergic reactions. High-dose loperamide 
was administered for delayed diarrhea, followed by 
prophylactic oral fluoroquinolones if diarrhea continued 
for over 48 h. Granulocyte colony-stimulating factor 
(G-CSF) was administered for severe neutropenia. 
AEs were assessed according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (version 4.03) before each cycle. In the event 
of predefined hematologic or non-hematologic AEs, 
protocol-specified treatment modifications or delays 
were performed to minimize additional treatment-
related AEs. 
For each patient, the study lasted up to 15 cycles 
with drugs donated by the pharmaceutical manufa-
cturers; patients who completed these cycles without 
PD were admitted to a post-study phase and continued 
chemotherapy according to the study protocol at their 
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own expense. Treatment was discontinued if PD or in-
tolerable toxicity was observed, if the patient withdrew 
from the study, or at the physician’s discretion. 
Data assessment
Pre-treatment evaluations included taking a complete 
medical history, physical examination, and laboratory 
tests. Evaluations were performed within 2 wk before, 
and every 2 wk during treatment. Tumor responses 
were assessed according to the Response Evaluation 
Criteria in Solid Tumors (version 1.1) based on high-
resolution computed tomography scans every 8 wk. 
QoL was assessed every 8 wk using the European Orga-
nization for Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire Core 30 (QLQ-C30)[12] 
and its supplement for patients with pancreatic cancer 
(QLQ-PAN26)[13]. Additionally, changes in body weight 
and pain scale were checked every 2 wk. The Korean 
version of the questionnaire, officially translated and 
distributed by EORTC, was used. All patients filled-out 
and submitted the questionnaire by themselves on the 
day of visit. QoL changes between baseline and the last 
visit were analyzed, considering that the participation 
period varied among patients. Scores of all QoL scales 
range from 0 to 100; a higher score indicates a better 
functional status or a worse symptom. 
Statistical analysis
When this clinical trial was being designed, the pre-
viously reported ORR of second-line chemotherapy 
for unresectable PC with GEM failure ranged from 0% 
to 11.4%[5,14-17]. With this background, this trial was 
performed according to a Simon optimal two-stage 
design (P0 = 0.100, P1 = 0.250, alpha = 0.050, and 
beta = 0.200; P0 and P1 are the response proportions 
of a poor and good drug, respectively)[18,19]. In the first 
stage, accepting a type Ⅰ error of 10% and a power 
of 80%, 46 patients were planned for enrollment. If 
three or fewer of the 22 enrolled patients demonstrated 
an objective response, we would terminate the experi-
ment at that stage based on the regimen’s low efficacy. 
Otherwise, the regimen would be recommended for 
further testing and accrual would continue to 46 patients 
(assuming a 15% dropout rate). 
All patients who received the study regimen at least 
once were included in the intention-to-treat (ITT) and 
toxicity analysis populations. All efficacy assessments 
were based on the ITT analyses. PFS and OS were 
estimated using Kaplan-Meier methods with 95% 
confidence interval (CIs). When comparing data (QoL 
questionnaire, weight, and pain scale) between baseline 
and last visit, the paired t-test was used for normally 
distributed data while the Wilcoxon signed rank test was 
used for non-normally distributed data. All statistical 
analyses were performed using IBM SPSS (version 
23.0, IBM Corp., Armonk, NY, United States). A P-value 
< 0.05 was considered statistically significant. 
RESULTS
Baseline characteristics of patients
Between August 2015 and May 2016, 48 patients were 
enrolled. The median age at the time of enrollment 
was 63.5 years [interquartile range (IQR), 57.5–69.0 
years]. All patients had cytologically or histologically 
confirmed adenocarcinoma according to the inclusion 
criteria. Also, all patients had LAPC or MPC including 38 
patients (79.2%) with accompanying distant metastasis 
(Table 1). Close to 80% of the patients received GEM 
plus erlotinib as their first-line GEM-based treatment. 
Because GEM plus nab-paclitaxel became available 
in January 2016 in Korea, only one patient was admi-
nistered this regimen prior to the study.
Treatment exposure
A flowchart of the 48 patients’ treatments is shown in 
Supplementary Figure 1; at the time of analysis, 38 of 
these patients had died while two patients remained 
on FOLFIRINOX with RIO. Treatment was discontinued 
prior to completing 15 cycles in 33 patients, including 
14 who showed PD, 10 who had treatment delays for 
unresolved infections (n = 2) or grade 3/4 toxicities 
(n = 8), five who declined further treatment, two who 
died after treatment (one of septic shock and the other 
of unknown reasons at another location), one who 
had acute cerebral infarction, and one who showed 
radiologic CR. All patients combined received a total 
of 493 cycles of chemotherapy. The median follow-up 
time was 259 d (IQR, 103.3–427.8 d), and the median 
number of chemotherapy cycles per patient was 8.5 
(IQR, 3.0–16.5), with a median treatment duration of 
145 d (IQR, 30.5–286.3 d). The relative dose intensity 
(proportion of the administered accumulated dose 
relative to the planned accumulated dose) of bolus 5-FU, 
infusional 5-FU, combined bolus plus infusional 5-FU, 
irinotecan, and oxaliplatin was 93.60% ± 15.86%, 
93.60% ± 15.86%, 93.60% ± 15.86%, 95.65% ± 
8.16%, and 95.65% ± 8.16%, respectively. 
Tumor responses and survival
Tumor responses and survival analysis are shown in 
Table 2. The ORR and DCR of all patients were 18.8% 
and 62.5%, respectively. The DCR was 80% in ten LAPC 
patients, but no CR or PR was reported. Among 38 MPC 
patients (79.2% of all patients), the ORR and DCR were 
23.7% and 57.9%, respectively. A sixty-year-old female 
patient, who progressed to multiple liver metastasis 
after GEM monotherapy, achieved radiologic CR after 
12 cycle of FOLFIRINOX with RIO. After twelfth cycle, 
the patient had not experienced disease recurrence on 
serial radiologic studies without chemotherapy for a 
year, until peritoneal seeding and liver metastasis were 
confirmed. 
The median PFS was 5.8 mo (95%CI: 3.7–7.9 mo) 
and the median OS was 9.0 mo (95%CI: 6.4–11.6 mo) 
for all patients (Figure 1). The PFS rates at 6, 12, and 
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18 mo were 47.9%, 27.1%, and 6.3%, respectively, 
while the OS rates at 6, 12, and 18 mo were 60.4%, 
37.5% and 10.4%, respectively. Eighteen patients 
(37.5%) survived more than 1 year. The estimated OS 
from the beginning of first-line treatment was 17.1 mo 
(95%CI: 10.6–23.6 mo). The median PFS and OS were 
respectively 5.4 and 8.4 mo for MPC patients, and 8.8 
and 12.5 mo for LAPC patients. Analysis of changes 
in laboratory tests between before and after therapy 
showed that the median CA19-9 significantly decreased 
from 366.3 (1–16351) to 311.7 (2–16287) U/mL (P = 
0.041). 
Safety analysis
AEs that occurred in more than 5% of the 48 patients 
are listed in Table 3. Common AEs observed in more 
than 20% of patients were neutropenia (68.8%), fati-
gue (22.9%), nausea and vomiting (66.7%), diarrhea 
(35.4%), oral mucositis (31.3%), anorexia (20.8%), 
and fever (20.8%). Of a total of 511 AEs, 358 (70.1%) 
were considered related to therapy, and 163 (31.9%) 
were severe AEs (grade 3 or 4). The most common 
severe AE was neutropenia (64.6%), followed by febrile 
neutropenia and fatigue (16.7% for both). None of 
the patients experienced severe nausea/vomiting or 
constipation. One patient died of septic shock related to 
grade 4 neutropenia after treatment. 
Changes in QoL
The average body weight was 58.9 ± 9.81 kg at 
baseline and 59.0 ± 9.83 kg at the last visit. The 
average pain scale (Visual Analogue Scale) at baseline 
and the last visit were 2.12 ± 2.31 and 1.90 ± 2.15, 
respectively. There were no significant changes in 
body weight and pain scale (P = 0.93 and P = 0.71, 
respectively). QoL questionnaires were available for 31 
patients. The global health status scores of the EORTC 
QLQ-C30 did not worsen after treatment (P = 0.548). 
In general, most functional scores were not significantly 
decreased except role and cognitive functioning (P = 
0.044 and P = 0.015, respectively) (Supplementary 
Table 1). Among symptom scores, fatigue and dyspnea 
were significantly worse than those in the pre-treatment 
period (P = 0.021 and P = 0.038, respectively). 
Among separate QLQ-PAN26 questions, worsening 
of dry mouth was observed (P = 0.011). In patients 
who achieved disease control (n = 29), the global 
health status score did not worsen after treatment, 
509WJGO|https://www.wjgnet.com December 15, 2018|Volume 10|Issue 12|
IQR: Interquartile range; ECOG-PS: Eastern Cooperative Oncology Group-performance status; CA 19-9: Carbohydrate antigen 19-9; GEM: Gemcitabine; 
ULN: Upper limit of the normal range; CCRT: Concurrent chemo-radiotherapy; CTx: Chemotherapy.
Characteristics of the patients n  = 48 Percent
Age (yr) median (IQR) 63.5 (57.5-69.0)
40-49   4   8.3
50-59 10 20.8
60-69 25 52.1
70-79   9 18.8
Sex Male 23 47.9
Female 25 52.1
ECOG-PS 0 22 45.8
1 24 50
2   2   4.2
Duration since diagnosis (mo) median (IQR) 7.0 (3.0-12.0)
Location of pancreatic cancer Head 18 37.5
Body and tail 17 35.4
Recurrence after resection 13 27.1
Number of metastatic site 0 10 20.8
1 18 37.5
2 14 29.2
≥ 3   6 12.5
Metastatic sites (> 5%) Liver 28 58.3
Peritoneum 16 33.3
Distant lymph node   8 16.7
Lung   6 12.5
Level of CA 19-9 Normal 10 20.8
> ULN 38 79.2
Prior GEM CTx GEM monotherapy   6 12.5
GEM + Erlotinib 38 79.2
GEM + Capecitabine   2   4.2
GEM + Cisplatin   1   2.1
GEM + Nab-paclitaxel   1   2.1
Period of prior CTx (mo) median (IQR) 4.1 (1.9-7.8)
Prior treatment other than CTx Operation 13 27.1
CCRT   6 12.5
Table 1  Baseline characteristics
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LAPC: Locally advanced pancreatic cancer; MPC: Metastatic pancreatic cancer; CR: Complete response; PR: Partial response; SD: Stable disease; PD: 
Progressive disease; ORR: Objective response rate; DCR: Disease control rate; CI: Confidence interval; PFS: Progression-free survival; OS: Overall survival; 
CTx: Chemotherapy.
All (n  = 48) LAPC (n  = 10) MPC (n  = 38)
Response, n (%)
   CR 1 (2.1) 0 (0.0) 1 (2.6)
   PR   8 (16.7) 0 (0.0)   8 (21.1)
   SD 21 (43.8)   8 (80.0) 13 (34.2)
   PD   7 (14.6)   1 (10.0)   6 (15.8)
   Could not be evaluated 11 (22.9)   1 (10.0) 10 (26.3)
   ORR   9 (18.8) 0 (0.0)   9 (23.7)
   DCR 30 (62.5)   8 (80.0) 22 (57.9)
Survival, mo (95%CI)
   Median PFS 5.8 (3.7-7.9)   8.8 (6.0-11.6) 5.4 (2.9-7.9)
   Median OS (from 2nd-line CTx)  9.0 (6.4-11.6) 12.5 (4.9-20.1)   8.4 (5.4-11.4)
   Median OS (from 1st-line CTx)  17.1 (10.6-23.6)   19.1 (13.8-24.4) 16.8 (8.8-24.8)
Table 2  Tumor responses and survivals (intention-to-treat population)
Progression-free survival
100
75
50
25
0
Number at risk
(number censored)  48(0)       32(1)       23(1)        16(1)       13(1)        5(2)          3(2)        0(3)
Months
Su
rv
iv
al
 (
%
)
0             3             6             9            12           15           18           21
Overall survival
100
75
50
25
0
Number at risk
(number censored)  48(0)       41(1)        29(2)       22(2)       18(2)       11(3)         5(6)       0(10)
Months
Su
rv
iv
al
 (
%
)
0             3             6             9            12           15           18           21
A
B
Figure 1  Kaplan-Meier analysis of survival data. A: The estimated median progression-free survival was 5.8 mo (95%CI: 3.7-7.9); B: The estimated median overall 
survival was 9.0 mo (95%CI: 6.4-11.6).
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but some individual items including cognitive function, 
fatigue, digestive symptoms, and dry mouth were 
significantly worsened. Only one item (future worries) 
was significantly improved (Supplementary Table 2). 
In patients who completed 15 cycles, constipation and 
pancreatic pain were significantly improved by the end 
of treatment; only digestive symptoms were aggravated 
(Supplementary Table 3).
DISCUSSION
FOLFIRINOX with RIO showed an acceptable toxicity 
profile and promising efficacy as a second-line treat-
ment for GEM-refractory unresectable PC. Although 
severe neutropenia occurred in almost 65% of parti-
cipants, other severe AEs, particularly non-hematologic 
AEs, were infrequently reported. Moreover, the global 
health status scores of the EORTC QLQ-C30 were not 
changed significantly after treatment. 
Second-line chemotherapy may be considered for 
many patients[20]. At present, there is no recognized 
standard for patients with unresectable PC who 
experience PD after first-line chemotherapy, and PFS 
is consistently < 4 mo in patients receiving second-line 
chemotherapy. A meta-analysis showed that median OS 
was 6.0 mo with chemotherapy versus 2.8 mo with best 
supportive care[21]. Patients whose cancers progress 
after first-line therapy have difficulty undergoing 
second-line chemotherapy since they are often older, 
unwell, and at risk of rapid deterioration[22]. 
Only a few prospective trials have shown encou-
raging results with oxaliplatin plus 5-FU using various 
doses and schedules[5,6,14,17,23]. Two phase Ⅲ trials pro-
duced conflicting results. The CONKO-003 trial com-
paring 5-FU plus FA (FF) and oxaliplatin plus FF (OFF) 
showed survival benefits of second-line OFF in patients 
with unresectable GEM-refractory PC[6]. In contrast, 
the PANCREOX trial evaluating the modified FOLFOX6 
(mFOLFOX6) found no difference in PFS, while the OS 
of mFOLFOX6 was inferior to that of FF[24]. 
Research on irinotecan plus 5-FU as second-line 
chemotherapy for PC was also performed[15,25]. The 
NAPOLI-1 phase Ⅲ trial comparing nanoliposomal irino-
tecan (nal-IRI) alone or combined with FF showed that 
the combination of nal-IRI and FF was more effective 
than FF alone, but caused more frequent severe AEs[7].
A recent comparative systematic review of four 
randomized trials evaluating oxaliplatin- or irinotecan-
containing regimens as post-GEM therapies for patients 
with unresectable PC showed significant dissimilarity 
between them; therefore, it is unclear which regimen is 
best-suited for patients with unresectable PC previously 
treated with GEM[26]. Table 4 summarizes clinical trials of 
second-line treatment for GEM-pre-treated unresectable 
PC. Our results using second-line FOLFIRINOX with 
RIO showed results that were superior to those in most 
previous trials.
Toxicities associated with standard FOLFIRINOX 
have prompted trials evaluating modifications of 
FOLFIRINOX[8-10]. These previous studies of FOLFIRINOX 
modifications suggested that upfront dose attenua-
tions of standard FOLFIRINOX can improve tolerability 
without reducing efficacy. A recent phase Ⅱ trial showed 
that the efficacy of first-line FOLFIRINOX with reduced 
doses of the 5-FU bolus and irinotecan was compar-
able to that of the standard regimen; furthermore, 
neutropenia, vomiting, and fatigue were significantly 
reduced[10]. However, only a few studies have evaluated 
FOLFIRINOX for patients with unresectable PC after 
failure of GEM-based chemotherapy; patients’ perfor-
mance statuses are likely to deteriorate after first-line 
treatment; necessitating second-line dose reductions 
as in our study. A Japanese phase Ⅱ trial used modi-
fied FOLFIRINOX reducing only irinotecan for 18 MPC 
patients[27]. Findings of that trial were consistent with 
our results except the PFS, which was longer in the 
present study (2.8 mo vs 5.8 mo).
FOLFIRINOX and nab-paclitaxel plus GEM are two 
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N = 48 n  (%)
Intensity according to the NCI-CTCAE v4.03
Grade 1 Grade 2 Grade 3 Grade 4
Non-hematologic
   Fatigue 11 (22.9) 3 (6.3) 0   8 (16.7) -
   Nausea and vomiting 32 (66.7) 17 (35.4) 15 (31.3) 0 0
   Diarrhea 17 (35.4)   7 (14.6)   9 (18.8) 1 (2.1) 0
   Constipation   8 (16.7) 4 (8.3) 4 (8.3) 0 0
   Oral mucositis 15 (31.3) 4 (8.3) 10 (20.8) 1 (2.1) 0
   Anorexia 10 (20.8)   9 (18.8) 0 1 (2.1) 0
   Peripheral neuropathy   7 (14.6)   6 (12.5) 0 1 (2.1) 0
   Biliary tract infection 3 (6.3) 0 0 3 (6.1) 0
   Fever 10 (20.8) 1 (2.1)   9 (18.8) 0 0
Hematologic
   Neutropenia 33 (68.8) 0 2 (4.2) 11 (22.9) 20 (41.7)
   Thrombocytopenia   6 (12.5) 0 1 (2.1) 1 (2.1) 4 (8.3)
   Febrile neutropenia   8 (16.7) - -   5 (10.4) 3 (6.3)
Table 3  Adverse events (≥ 5%)
NCI: National Cancer Institute; CTCAE: Common Terminology Criteria for Adverse Events.
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unique dose modification called “FOLFIRINOX with RIO”.
In our study, the relatively higher incidences of 
severe neutropenia may be related to the patients’ 
deteriorated physical status after first-line chemothe-
rapy and the lack of prophylactic G-CSF support. For 
non-hematologic AEs, no grade 3 or 4 vomiting was 
observed, unlike in the PRODIGE 4/ACCORD 11 trial[3]. 
This improved non-hematologic tolerability may be 
related to the routine administration of prophylactic 
palonosetron during every cycle of treatment. Peripheral 
neuropathy was also significantly reduced compared 
with the previous study, likely because of oxaliplatin 
dose reduction. In comparison with nal-IRI plus 5-FU 
regimen of the NAPOLI-1 trial, the preferred second-line 
therapy for MPC in current guidelines[31,32], most severe 
non-hematologic AEs of the present study occurred at 
lower rates (diarrhea, 13% vs 2.1%; vomiting, 11% 
vs 0%; anorexia, 4% vs 2.1%)[7]. However, the rate 
of severe neutropenia was much higher in the present 
study (27% vs 64.6%).
Considering QoL, some functional scales such as 
role and cognitive functioning were significantly reduced 
in our patients, and some symptom scales such as 
fatigue and dyspnea were significantly worsened. 
However, these changes were predictable given our 
patients’ ages and performance statuses. Global QoL 
indicators did not significantly deteriorate; moreover, 
the “physical functioning” QoL score (regarded as one of 
the strongest prognostic values[33]) did not significantly 
worsen throughout treatment.
This study had several limitations. First, it was a 
non-randomized, single arm trial with a relatively small 
sample size. A prospective randomized trial including 
sufficient patients is warranted to provide the clinical 
recommendation about the treatment sequence for 
MPC. Second, we included patients with LAPC and 
MPC who were treated with various prior GEM-based 
regimens. This heterogeneity in patient population and 
first-line chemotherapy regimens needs to be improved 
in future research. 
In conclusion, FOLFIRINOX with RIO showed en-
couraging results in terms of efficacy, with an acce-
ptable safety profile. In addition to nal-IRI plus 5-FU 
regimen, FOLFIRINOX with RIO may be considered 
as a treatment option in patients with GEM-refractory 
unresectable PC. Because the condition of such pa-
tients can quickly deteriorate owing to rapid disease 
progression and treatment toxicity, this regimen may 
provide acceptable tolerability for patients in terms of 
patient QoL. However, the presence of hematologic 
toxicities should be carefully observed, nevertheless, 
and the routine use of G-CSF should be considered to 
minimize the risk of hematologic toxicities. 
ARTICLE HIgHLIgHTS 
Research background
Proper second-line treatment can improve survival of patients with unresectable 
pancreatic cancer (PC) who fail first-line treatment with gemcitabine (GEM)-
based regimen. Although some previous phase Ⅲ trials showed survival 
improvement with their study regimens, the standard second-line treatment 
remains unclear.
Research motivation
FOLFIRINOX, a standard first-line treatment for PC, has been proposed as a 
second-line treatment regimen; however, concerns about relatively high toxicity 
limited broad use of FOLFIRINOX as a second-line therapy. 
Research objectives
We evaluated the efficacy and safety of modified dose of FOLFIRINOX as a 
second-line treatment for GEM-refractory unresectable PC.
Research methods
In this prospective, multicenter, one-arm, open-label, phase Ⅱ trial, unresectable 
PC patients, who showed disease progression during GEM-based therapy were 
enrolled. All patients were administered FOLFIRINOX with reduced irinotecan 
and oxaliplatin (RIO; irinotecan 120 mg/m2 and oxaliplatin 60 mg/m2), which 
was set according to the previous phase Ⅰ study of FOLFIRINOX, with the 
standard dose of 5-fluorouracil (5-FU). The objective response rate (ORR), 
disease control rate (DCR), progression-free survival (PFS), overall survival 
(OS), adverse events, and changes in quality of life (QoL) were evaluated.
Research results
A total of 48 patients were enrolled in eight Korean centers. The ORR and 
DCR were 18.8% and 62.5%, respectively, including one patient who showed 
complete remission. The median PFS was 5.8 mo [95% confidence interval (CI): 
3.7-7.9] and median OS was 9.0 mo (95%CI: 6.4-11.6). Neutropenia (64.6%) 
was the most common grade 3-4 adverse event. Although 14.6% of patients 
experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. 
In the QoL analysis, the global health status score before treatment was not 
different from the score at the last visit after treatment (45.43 ± 22.88 vs 48.66 
± 24.14, P = 0.548).
Research conclusions
FOLFIRINOX with RIO showed acceptable tolerability for patients in terms of 
patient QoL and may be considered as a treatment option in patients with GEM-
refractory unresectable PC. However, the presence of hematologic toxicities 
should be carefully observed and the routine use of granulocyte colony-
stimulating factor should be considered to minimize the risk of hematologic 
toxicities. 
Research perspectives
Prospective study with larger population comparing the efficacy and safety 
between FOLFIRINOX with RIO and 5-FU plus leucovorin needs to be 
conducted. 
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